HomeREGULATORY
REGULATORY

“Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
(Jan.20.2016)

A total of six products of four brands - Sovaldi (sofosbuvir), Harvoni (ledipasvir + sofosbuvir), Avastin (bevacizumab), and Plavix (clopidogrel) - will face a new special re-pricing rule to be rolled out in April for drugs generating “huge sales.”

The plan was reported by the Ministry of Health, Labor and Welfare (MHLW) at a general meeting of the Central Social Insurance Medical Council (Chuikyo) on January 20.
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 28.

News Calendar